Work Here?
Overview
Bodyport provides at-home, noninvasive heart-health monitoring through a digital biomarker platform. At-home devices collect hemodynamic data, which the biomarker platform translates into actionable insights and alerts for patients and care teams. This integrated approach combines easy-to-use devices with continuous data analysis to support remote management of heart failure and related conditions. The goal is to reduce hospital visits and improve outcomes by delivering timely, meaningful health insights outside the clinic.
About Bodyport
Industries
Data & Analytics
Enterprise Software
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$16M
Headquarters
San Francisco, California
Founded
2015
Simplify's Take
What believers are saying
- Geisinger partnership launches heart failure monitoring program expanding access.
- SCALE-HF study validates composite index for early heart failure prediction.
- John Lipman appointed CEO drives medtech commercialization expertise.
What critics are saying
- Ventricular Care's FreeScale erodes market share with lower-cost AI scale.
- FDA audits Bodyport's algorithms post-Biobeat recall halt Geisinger rollout.
- Onera Health poaches partners using Lipman's superior cardiorenal patch.
What makes Bodyport unique
- Bodyport Cardiac Scale noninvasively measures hemodynamic biomarkers via single step.
- Congestion Index algorithm detects worsening heart failure twice as sensitively.
- FDA-cleared platform integrates with EHRs and supports RPM billing.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$16M
Below
Industry Average
Funded Over
5 Rounds
Y CombinatorIndustry standards
Growth & Insights and Company News
6 month growth
↓ -6%1 year growth
↑ 0%2 year growth
↑ 0%Bodyport and Geisinger to launch innovative Heart failure monitoring program.
Bodyport Inc. today introduced SCALE-HF, a multi-phase study to develop and validate a composite index to predict heart failure events using multiple noninvasive hemodynamic biomarkers gathered when a patient stands on the Bodyport Cardiac Scale.
Bodyport, a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions, announced today the appointment of Jim Pursley to the company’s board of directors.
Biomarker-guided digital therapeutics company Bodyport has appointed medtech industry veteran John Lipman as its new CEO.
Jess asks me about Lumeon raising a $30M Series D for their care orchestration centers, Nurx raising a $22M Series C to develop out its online pharmacy presence, Thirty Madison getting $47M and Johnson & Johnson is an investor this round, Bodyport closing an $11.2 M Series A for their weighing scale platform that can detect early cardiovascular disease, and Kumanu raising a $3M Series A to grow out its platform that helps people figure out their lives’ purpose.
There are no jobs for Bodyport right now.
Find jobs on Simplify and start your career today
About Bodyport
Industries
Data & Analytics
Enterprise Software
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$16M
Headquarters
San Francisco, California
Founded
2015
There are no jobs for Bodyport right now.
Find jobs on Simplify and start your career today